ArQule (ARQL) Stock Price, News & Analysis

Company Overview

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.

Key Stats

• Today's Range: $20.00 to $20.00
• 50-Day Range: $20.00 to $20.00
• 52-Week Range: $3.15 to $20.45
• Volume: N/A
• Average Volume: 5.27 million shs
• Market Capitalization: $2.42 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ARQL Stock Analysis - Frequently Asked Questions

How were ArQule's earnings last quarter?

ArQule, Inc. (NASDAQ:ARQL) posted its earnings results on Wednesday, October, 30th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.01. The biotechnology company had revenue of $0.21 million for the quarter, compared to the consensus estimate of $1.20 million. ArQule had a negative trailing twelve-month return on equity of 33.10% and a negative net margin of 805.61%.

What other stocks do shareholders of ArQule own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ArQule investors own include Amarin (AMRN), Verastem (VSTM), Celldex Therapeutics (CLDX), Corbus Pharmaceuticals (CRBP), Advanced Micro Devices (AMD), Novavax (NVAX) and Axsome Therapeutics (AXSM).

Company Calendar

• Last Earnings: 10/30/2019
• Today: 8/07/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ARQL
• CIK: 1019695
• Web: www.arqule.com
• Phone: 781-994-0300
• Fax: N/A
• Employees: 36
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.48 million
• Net Margins: -805.61%
• Pretax Margin: N/A
• Return on Equity: -33.10%
• Return on Assets: -26.87%

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 8.27
• Quick Ratio: 8.27

Sales & Book Value

• Annual Sales: $25.76 million
• Price / Sales: 93.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.72 per share
• Price / Book: 27.78

Miscellaneous

• Outstanding Shares: 120,873,000
• Free Float: N/A
• Market Cap: $2.42 billion
• Optionable: Optionable
• Beta: 2.49